Biopharma companies develop medicines, vaccines and advanced therapies to prevent, treat and manage disease. The sector spans drug discovery, clinical development, manufacturing and commercialisation across a wide range of therapeutic areas.
This category includes companies working on:
Browse 304 UK biopharma companies below.
CSF-1R antibody therapy for tenosynovial giant cell tumour
SynOx Therapeutics is a late-stage biopharmaceutical company developing emactuzumab, a humanised monoclonal antibody targeting CSF-1R, for the treatment of tenosynovial giant cell tumour and other macrophage-driven conditions. Emactuzumab was licensed from Roche and inhibits the CSF-1 receptor to deplete…
Global pharmaceutical company developing medicines across major disease areas
AstraZeneca is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of prescription medicines. Its pipeline and product portfolio span oncology, cardiovascular and metabolic disease, respiratory and immunology, rare diseases, and vaccines. The company…
Cancer immunotherapies targeting novel antigens from the dark genome
Enara Bio is a clinical-stage biopharmaceutical company developing cancer immunotherapies directed against Dark Antigens, a class of cancer-specific targets derived from previously uncharted genomic dark matter. Its platform integrates bioinformatics, immunopeptidomics, and immunology to discover and validate novel…
DUB inhibitor therapeutics targeting mitophagy and degenerative disease
Mission Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule inhibitors of deubiquitylating enzymes to treat diseases driven by mitochondrial dysfunction. By targeting a mitochondria-localised DUB, the company's drug candidates are designed to enhance mitophagy, the cellular…
Precision oncology drugs and vaccines for cold tumours
IngenOx Therapeutics Limited is a clinical-stage biopharmaceutical company developing precision oncology drugs and cancer vaccines for difficult-to-treat tumours. The company serves oncology patients and clinical development partners through a pipeline spanning small molecule immunomodulators, PRMT5 inhibition and…
Specialist pharma acquiring and developing rare disease therapeutics
Ambrose Healthcare is a UK specialist pharmaceutical company developing treatments for rare diseases and patients in hospital and specialist care settings. The company builds its pipeline through the acquisition and licensing of late-stage clinical assets with existing human safety and efficacy data, targeting…
Targeted radiotheranostics for treatment-resistant solid tumours
Nuclide Therapeutics is a King's College London spin-out developing targeted radiopharmaceuticals for treatment-resistant solid tumours. Its radiotheranostic approach uses tumour-binding molecules labelled with diagnostic or therapeutic radionuclides to identify and attack cancer cells. Lead programmes target ALDH1A1…
Oral small molecule therapies for rare hereditary diseases
KalVista Pharmaceuticals is a biopharmaceutical company specialising in the discovery and commercialisation of oral small molecule protease inhibitors for rare diseases with significant unmet need. The company's lead programme targets the kallikrein-kinin system and has produced an approved oral on-demand therapy for…
Preclinical inhibitors of Notch and Mastermind cancer signalling pathways
Anastasis Biotec is a preclinical biotechnology company developing targeted inhibitors of cancer signalling pathways, with a focus on the Notch pathway and its transcriptional co-activator Mastermind. These pathways help drive tumour growth and the survival of cancer stem cells. The company is developing peptide-based…
Data-driven cis-bispecific antibody-drug conjugates for solid tumour cancers
Promatix Biosciences is an oncology drug discovery company developing next-generation bispecific antibody-drug conjugates through data-driven target pairing. Using a proteomics database and computational algorithms, the company identifies antigen combinations enabling selective tumour targeting, aiming to reduce…
Global biopharma focused on severe neurological and immunological diseases
UCB Pharma is the UK subsidiary of UCB S.A., a Belgian biopharmaceutical company focused on the discovery and development of treatments for severe neurological and immunological diseases. The UK operation is one of UCB's three global R&D hubs, with capabilities spanning antibody discovery, small molecule development,…
Global specialist pharmaceutical company focused on HIV
ViiV Healthcare is a specialist pharmaceutical company dedicated to the research, development, and commercialisation of medicines for HIV treatment and prevention. Its portfolio includes widely used antiretroviral therapies such as Dovato and the long-acting injectable Cabenuva, and it is advancing next-generation…
Clinical-stage biotech developing treatments for multiple myeloma
CellCentric is a clinical-stage biopharmaceutical company developing inobrodib, a first-in-class oral inhibitor of the p300/CBP transcription co-activation proteins, for relapsed and refractory multiple myeloma. Inobrodib has been evaluated in over 400 patients and holds FDA Fast Track and orphan drug designations.…
Small molecule therapeutics targeting lipid-signalling pathways
Artelo Biosciences is a clinical-stage biopharmaceutical company developing small molecule therapeutics that modulate lipid-signalling pathways, including the endocannabinoid system. Its pipeline includes ART27.13, a peripherally selective cannabinoid receptor agonist in Phase 2 for cancer-associated anorexia and…
Intestinal barrier repair therapies for inflammatory bowel disease
Thelior Bio is a University of Oxford spin-out developing therapies for inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Its research focuses on restoring the intestinal epithelial barrier, addressing impaired tissue repair associated with chronic inflammation. The company draws on…
Precision small molecule drugs for obsessive-compulsive disorder
Serenatis Bio is a preclinical-stage biotech developing small molecule drugs to treat obsessive-compulsive disorder (OCD). Its pipeline of three candidates targets distinct neurological mechanisms, including glutamate, AMPA, and dopamine pathways, with a biomarker-driven approach designed to match patients to…
T cell immunotherapies for infectious disease, cancer and autoimmunity
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific T cell immunotherapies for chronic infectious diseases, autoimmune conditions, and cancer. Its pipeline is built on four proprietary viral vector and synthetic immunotherapy platforms and includes clinical candidates…
Off-the-shelf cancer immunotherapies targeting solid tumours
Scancell is a clinical-stage biotech developing active immunotherapies and antibody-based therapeutics for cancer. Its pipeline spans DNA cancer vaccines, peptide immunotherapies and tumour-specific monoclonal antibodies targeting glycans expressed on cancer cells. Lead programmes iSCIB1+ and Modi-1 are in Phase 2…
Global commercialisation of specialty, hospital and rare disease medicines
ADVANZ PHARMA is a global pharmaceutical company focused on the commercialisation of specialty, hospital and rare disease medicines, partnering with biopharma and pharmaceutical development companies to bring treatments to patients. The company's portfolio spans therapeutic areas including hepatology,…
Small molecule therapeutics targeting astrocytes in Parkinson's disease
Cellestial Health is a pre-clinical stage biotechnology company and University of Cambridge spinout developing small molecule therapeutics for Parkinson's disease and other neurodegenerative conditions. The company's approach targets astrocytic networks, a class of brain cells whose dysregulation contributes to…